Evidence map›Paper›PMID 26909291›Full record

ArticleJournal of bone oncology2014

Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.

Xiaofu Zhu, Eitan Amir, Gurmit Singh, Mark Clemons, Christina Addison

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaofu ZhuDivision of Medical Oncology, Ottawa Hospital and Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Eitan AmirDivision of Medical Oncology and Hematology, University of Toronto and Princess Margaret Hospital, Toronto, Canada.
Gurmit SinghDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.
Mark ClemonsDivision of Medical Oncology, Ottawa Hospital and Faculty of Medicine, University of Ottawa, Ottawa, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Christina AddisonCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The annual Bone and The Oncologist New Updates (BONUS 8) conference focuses on the current understanding and dilemmas in the treatment and prevention of bone metastasis in cancer, as well as novel research on bone homeostasis and cancer-induced bone loss. We present commentaries from experts for their own take on where they feel the field of bone-targeted therapies for metastatic breast cancer is moving, or needs to move, if we are to make further progress.

Indexed as

Bone metastasisBreast cancerMeeting summaryOncodynamicsTargeted therapy

Identifiers

PMID26909291
PMCPMC4723414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.